Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques

Marcio O. Lasaro, Larissa H. Haut, Xiangyang Zhou, Zhiquan Xiang, Dongming Zhou, Yan Li, Wynetta Giles-Davis, Hua Li, Jessica C. Engram, Lauren J. Dimenna, Ang Bian, Marina Sazanovich, Elizabeth M. Parzych, Raj Kurupati, Juliana C. Small, Te Lang Wu, Rachel M. Leskowitz, Nichole Klatt, Jason M. Brenchley, David A. GarberMark Lewis, Sarah J. Ratcliffe, Michael R. Betts, Guido Silvestri, Hildegund C. Ertl

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Despite enormous efforts by the scientific community, an effective HIV vaccine remains elusive. To further address to what degree T cells in absence of antibodies may protect against simian immunodeficiency virus (SIV) disease progression, rhesus macaques were vaccinated intramuscularly with a chimpanzee-derived Ad vector (AdC) serotype 6 and then boosted intramuscularly with a serologically distinct AdC vector of serotype 7 both expressing Gag of SIVmac239. Animals were subsequently boosted intramuscularly with a modified vaccinia Ankara (MVA) virus expressing Gag and Tat of the homologous SIV before mucosal challenge with a high dose of SIVmac239 given rectally. Whereas vaccinated animals showed only a modest reduction of viral loads, their overall survival was improved, in association with a substantial protection from the loss of CD4 T cells. In addition, the two vaccinated Mamu-A01 macaques controlled viral loads to levels below detection within weeks after challenge. These data strongly suggest that T cells, while unable to affect SIV acquisition upon high-dose rectal infection, can reduce disease progression. Induction of potent T-cell responses should thus remain a component of our efforts to develop an efficacious vaccine to HIV-1.

Original languageEnglish (US)
Pages (from-to)417-426
Number of pages10
JournalMolecular Therapy
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Macaca mulatta
Simian Immunodeficiency Virus
Vaccines
T-Lymphocytes
Viral Load
Disease Progression
AIDS Vaccines
Pan troglodytes
Vaccinia virus
Macaca
Virus Diseases
HIV-1
Survival
Antibodies
Infection
Serogroup

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Lasaro, M. O., Haut, L. H., Zhou, X., Xiang, Z., Zhou, D., Li, Y., ... Ertl, H. C. (2011). Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. Molecular Therapy, 19(2), 417-426. https://doi.org/10.1038/mt.2010.238

Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. / Lasaro, Marcio O.; Haut, Larissa H.; Zhou, Xiangyang; Xiang, Zhiquan; Zhou, Dongming; Li, Yan; Giles-Davis, Wynetta; Li, Hua; Engram, Jessica C.; Dimenna, Lauren J.; Bian, Ang; Sazanovich, Marina; Parzych, Elizabeth M.; Kurupati, Raj; Small, Juliana C.; Wu, Te Lang; Leskowitz, Rachel M.; Klatt, Nichole; Brenchley, Jason M.; Garber, David A.; Lewis, Mark; Ratcliffe, Sarah J.; Betts, Michael R.; Silvestri, Guido; Ertl, Hildegund C.

In: Molecular Therapy, Vol. 19, No. 2, 01.01.2011, p. 417-426.

Research output: Contribution to journalArticle

Lasaro, MO, Haut, LH, Zhou, X, Xiang, Z, Zhou, D, Li, Y, Giles-Davis, W, Li, H, Engram, JC, Dimenna, LJ, Bian, A, Sazanovich, M, Parzych, EM, Kurupati, R, Small, JC, Wu, TL, Leskowitz, RM, Klatt, N, Brenchley, JM, Garber, DA, Lewis, M, Ratcliffe, SJ, Betts, MR, Silvestri, G & Ertl, HC 2011, 'Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques', Molecular Therapy, vol. 19, no. 2, pp. 417-426. https://doi.org/10.1038/mt.2010.238
Lasaro, Marcio O. ; Haut, Larissa H. ; Zhou, Xiangyang ; Xiang, Zhiquan ; Zhou, Dongming ; Li, Yan ; Giles-Davis, Wynetta ; Li, Hua ; Engram, Jessica C. ; Dimenna, Lauren J. ; Bian, Ang ; Sazanovich, Marina ; Parzych, Elizabeth M. ; Kurupati, Raj ; Small, Juliana C. ; Wu, Te Lang ; Leskowitz, Rachel M. ; Klatt, Nichole ; Brenchley, Jason M. ; Garber, David A. ; Lewis, Mark ; Ratcliffe, Sarah J. ; Betts, Michael R. ; Silvestri, Guido ; Ertl, Hildegund C. / Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques. In: Molecular Therapy. 2011 ; Vol. 19, No. 2. pp. 417-426.
@article{b653a80f65a44496be587b295c6da2c9,
title = "Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques",
abstract = "Despite enormous efforts by the scientific community, an effective HIV vaccine remains elusive. To further address to what degree T cells in absence of antibodies may protect against simian immunodeficiency virus (SIV) disease progression, rhesus macaques were vaccinated intramuscularly with a chimpanzee-derived Ad vector (AdC) serotype 6 and then boosted intramuscularly with a serologically distinct AdC vector of serotype 7 both expressing Gag of SIVmac239. Animals were subsequently boosted intramuscularly with a modified vaccinia Ankara (MVA) virus expressing Gag and Tat of the homologous SIV before mucosal challenge with a high dose of SIVmac239 given rectally. Whereas vaccinated animals showed only a modest reduction of viral loads, their overall survival was improved, in association with a substantial protection from the loss of CD4 T cells. In addition, the two vaccinated Mamu-A01 macaques controlled viral loads to levels below detection within weeks after challenge. These data strongly suggest that T cells, while unable to affect SIV acquisition upon high-dose rectal infection, can reduce disease progression. Induction of potent T-cell responses should thus remain a component of our efforts to develop an efficacious vaccine to HIV-1.",
author = "Lasaro, {Marcio O.} and Haut, {Larissa H.} and Xiangyang Zhou and Zhiquan Xiang and Dongming Zhou and Yan Li and Wynetta Giles-Davis and Hua Li and Engram, {Jessica C.} and Dimenna, {Lauren J.} and Ang Bian and Marina Sazanovich and Parzych, {Elizabeth M.} and Raj Kurupati and Small, {Juliana C.} and Wu, {Te Lang} and Leskowitz, {Rachel M.} and Nichole Klatt and Brenchley, {Jason M.} and Garber, {David A.} and Mark Lewis and Ratcliffe, {Sarah J.} and Betts, {Michael R.} and Guido Silvestri and Ertl, {Hildegund C.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1038/mt.2010.238",
language = "English (US)",
volume = "19",
pages = "417--426",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques

AU - Lasaro, Marcio O.

AU - Haut, Larissa H.

AU - Zhou, Xiangyang

AU - Xiang, Zhiquan

AU - Zhou, Dongming

AU - Li, Yan

AU - Giles-Davis, Wynetta

AU - Li, Hua

AU - Engram, Jessica C.

AU - Dimenna, Lauren J.

AU - Bian, Ang

AU - Sazanovich, Marina

AU - Parzych, Elizabeth M.

AU - Kurupati, Raj

AU - Small, Juliana C.

AU - Wu, Te Lang

AU - Leskowitz, Rachel M.

AU - Klatt, Nichole

AU - Brenchley, Jason M.

AU - Garber, David A.

AU - Lewis, Mark

AU - Ratcliffe, Sarah J.

AU - Betts, Michael R.

AU - Silvestri, Guido

AU - Ertl, Hildegund C.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Despite enormous efforts by the scientific community, an effective HIV vaccine remains elusive. To further address to what degree T cells in absence of antibodies may protect against simian immunodeficiency virus (SIV) disease progression, rhesus macaques were vaccinated intramuscularly with a chimpanzee-derived Ad vector (AdC) serotype 6 and then boosted intramuscularly with a serologically distinct AdC vector of serotype 7 both expressing Gag of SIVmac239. Animals were subsequently boosted intramuscularly with a modified vaccinia Ankara (MVA) virus expressing Gag and Tat of the homologous SIV before mucosal challenge with a high dose of SIVmac239 given rectally. Whereas vaccinated animals showed only a modest reduction of viral loads, their overall survival was improved, in association with a substantial protection from the loss of CD4 T cells. In addition, the two vaccinated Mamu-A01 macaques controlled viral loads to levels below detection within weeks after challenge. These data strongly suggest that T cells, while unable to affect SIV acquisition upon high-dose rectal infection, can reduce disease progression. Induction of potent T-cell responses should thus remain a component of our efforts to develop an efficacious vaccine to HIV-1.

AB - Despite enormous efforts by the scientific community, an effective HIV vaccine remains elusive. To further address to what degree T cells in absence of antibodies may protect against simian immunodeficiency virus (SIV) disease progression, rhesus macaques were vaccinated intramuscularly with a chimpanzee-derived Ad vector (AdC) serotype 6 and then boosted intramuscularly with a serologically distinct AdC vector of serotype 7 both expressing Gag of SIVmac239. Animals were subsequently boosted intramuscularly with a modified vaccinia Ankara (MVA) virus expressing Gag and Tat of the homologous SIV before mucosal challenge with a high dose of SIVmac239 given rectally. Whereas vaccinated animals showed only a modest reduction of viral loads, their overall survival was improved, in association with a substantial protection from the loss of CD4 T cells. In addition, the two vaccinated Mamu-A01 macaques controlled viral loads to levels below detection within weeks after challenge. These data strongly suggest that T cells, while unable to affect SIV acquisition upon high-dose rectal infection, can reduce disease progression. Induction of potent T-cell responses should thus remain a component of our efforts to develop an efficacious vaccine to HIV-1.

UR - http://www.scopus.com/inward/record.url?scp=79551653511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551653511&partnerID=8YFLogxK

U2 - 10.1038/mt.2010.238

DO - 10.1038/mt.2010.238

M3 - Article

C2 - 21081905

AN - SCOPUS:79551653511

VL - 19

SP - 417

EP - 426

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -